Stock Ratings / Health Care / BMGL / forecast

PIII (24) EUDA (35) DCGO (41) ALPS (50) ⌘ Pro Terminal →

Basel Medical Group Ltd (BMGL) 12-Month Stock Forecast & Price Target Cone

$5.04 +6.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.09

Basel Medical Group Ltd (BMGL) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $36.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMGL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BMGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Basel Medical Group Ltd (NASDAQ: BMGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $5.04 (+6.11% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BMGL ranks #261 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BMGL compare to PIII and EUDA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), BMGL carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PIII (P3 Health Partners Inc. (Class A)) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $30.5M) and EUDA (EUDA Health Holdings Limited) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, BMGL leads on earnings multiple (N/A) while PIII leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMGL?

▼

For Basel Medical Group Ltd (BMGL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #261 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.09 (+0.91%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMGL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY BMGL SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.71+9.2% Next Q

Q2 (-2Q)

Grade D$4.05+12.3% Next Q

Q3 (-1Q)

Grade C-$4.55+10.8% Next Q

Current

Grade D+$5.04-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BMGL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BMGL currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.36) and Max Pain ($5.29) forces dealer call-delta covering toward $19.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BMGL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BMGL Position Size: $10,000

Shares at $5.04: 1984.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.85

$7,639

$-2,361 (-23.6%)

12M Consensus BaseTarget $4.93

$9,782

$-218 (-2.2%)

12M Bull Case BreakoutTarget $19.66

$39,008

+$29,008 (+290.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$5	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$18	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMGL)

✓Walkthrough of BMGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BMGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.38%▼ DESCENDING CHANNEL

2026-11-02O $4.60H $5.04L $4.60C $5.04VOL 1.32M

RES: $8.25SUP: $1.91SMA50: $4.36SMA200: $6.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMGL Butterfly Map → + Track BMGL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BMGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BMGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMGL)

Health Care Rank #261 of 1016 ⚔️ PIII vs BMGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMGL vs. PIII, EUDA, DCGO, ALPS)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Basel Medical Group Ltd (BMGL) ranks #261 by composite RQD confidence (53/100, grade D+) and #787 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, BMGL leads on earnings valuation at N/A trailing P/E, while PIII leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BMGL ACTIVE Basel Medical Group Ltd	D+	53/100	—	—	—	+6.11%	$36.0M	Benchmark Subject
PIII P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$30.5M	/piii-vs-bmgl →
EUDA EUDA Health Holdings Limited	D-	35/100	—	43.9%	-35.0%	+14.19%	$46.4M	/euda-vs-bmgl →
DCGO DocGo Inc.	D-	41/100	—	—	-35.0%	-9.59%	$27.0M	/dcgo-vs-bmgl →
ALPS ALPS Group Inc Ordinary Share	D	50/100	—	—	—	+0.03%	$54.1M	/alps-vs-bmgl →

2. BMGL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Basel Medical Group Ltd (BMGL) operates in Medical/Nursing Services (Health Care) with an equity capitalization of $36.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BMGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BMGL compare to PIII and EUDA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BMGL?

Where is BMGL trading relative to its 50-day, 200-day, and 52-week technical levels?

BMGL last traded at $5.04 (+6.11% on volume of 1,782,262 shares), positioning the stock +15.60% above its 50-day simple moving average ($4.36) and -21.98% below its 200-day simple moving average ($6.46). Across its 52-week range of $2.56 to $18.72, BMGL sits at the 15.3% percentile with a 14-day RSI of 59.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.41 to $5.67).

BMGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BMGL's 12-month stock price target?

Basel Medical Group Ltd (BMGL) carries a 12-month consensus base price target of $4.93 (-2.2% from $5.04), with a bull-case target of $19.66 and a bear-case floor of $3.85.

Is BMGL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BMGL D+ (Sell — SELL) with an RQD Confidence score of 53/100.

Direct Sub-Reports: BMGL RQD Cockpit BMGL 12M Forecast BMGL Earnings & Move BMGL Dividends & DRIP BMGL Insiders & 13F BMGL Whale Options BMGL Profit Sankey BMGL News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BMGL — Basel Medical Group Ltd: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:33Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BMGL scores 53 out of 100, equating to a D+ grade and the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 12 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 9 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the cash engine pillar is the weakest signal: the rating reports zero ROIC and zero FCF yield, meaning the source data shows no measured return on invested capital or free cash generation to support the valuation. The balance sheet pillar is the relative strength, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 indicating a moderate forensic profile. Institutional and insider pillars both sit at 9 of 20, indicating limited measurable conviction signals. Macro fit at 10 of 20 reflects a beta of 1.0, meaning the stock is reported to move in line with the broad market. Upside drivers would require improvement in cash generation; the source data does not provide evidence of that improvement. Valuation tradeoffs cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the headlines reference a registered direct offering priced for BMGL, a completed stock offering accompanied by warrants, a reported 8.06% premarket decline, and a Q4 2026 earnings results report. Each item is tagged YELLOW with the MARKET WIRE impact label. The headline text in the feed is limited to titles and summaries; the earnings results and offering terms are not included in the source data. Risk watch items include the dilutive nature of an offering with accompanying warrants, as referenced in the feed headlines. No proprietary signals are present in the supply-chain graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are not available in source data. Sector correlation data is not available in source data beyond the Health Care sector classification. Second-order bottlenecks cannot be identified from the sources.

Open Questions

What is the company's revenue, net income, and free cash flow history, given that the financials section is empty?
What are the terms and dilution impact of the registered direct offering and accompanying warrants referenced in the news feed?
What are the company's products, customers, and revenue sources, since the profile does not describe its business?
What is the debt load and cash position behind the reported Debt/Equity of 0.5?
What do institutional holders, insiders, and analysts currently report, given that holders and analyst data are empty?

BMGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Basel Medical Group Ltd (BMGL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BMGL Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 15h ago

BMGL: Basel Medical Group Ltd Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering

Yahoo! Finance Canada report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Basel Medical Group Ltd Estimates – NASDAQ:BMGL

TradingView report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Six million warrants accompany Basel Medical Group (BMGL)'s completed stock offering.

Stock Titan report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

What Explains the 8.06% Premarket Decline for Basel Medical (NASDAQ:BMGL)?

Kalkine report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Basel Medical Group Q4 2026 Earnings Results and Report

MarketBeat report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Which of Allot (NASDAQ:ALLT), Borr Drilling (NYSE:BORR), LeonaBio (NASDAQ:LONA), Avax One Technology (NASDAQ:AVX) or Basel Medical Group (NASDAQ:BMGL) Is the Best of the Quiet Movers With No Clear Catalyst?

kalkine.ca report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Employee costs rose 44.4% as revenue grew at Basel Medical (Nasdaq: BMGL).

Stock Titan report covering Basel Medical Group Ltd (BMGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMGL Bull vs. Bear Conversation Board — What's Your Call at $5.04?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMGL 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $5.13 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BMGL (D+ • RQD 53/100) a Buy at $4.75?

Welcome to the BMGL (Basel Medical Group Ltd) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.85 (-18.9%)

Spot @ $4.75

Pump the brakes on BMGL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BMGL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Basel Medical Group Ltd expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.80 (+22.1%)

Spot @ $4.75

BMGL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BMGL, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $4.75 (52-wk range $2.56 - $18.72), any beat on forward guidance forces shorts and underweight funds to chase.